Physician profile
Reuben E Abraham
NPI 1245522143
$3,482.86
in general payments reported to CMS, 2019-2025
24 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.31 · 2022: $39.73 · 2023: $831 · 2024: $1,133 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $494.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $471.40 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $386.03 | 2023-2025 | Qulipta, Synthroid, Ubrelvy |
| Glaxosmithkline, LLC. | $200.99 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $164.52 | 2023-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $161.44 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $105.51 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $72.84 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $72.54 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $71.48 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $63.25 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.18 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $58.95 | 2025 | Gardasil 9, Capvaxive |
| Pfizer INC. | $51.10 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $51.05 | 2025 | Nexletol |
| Astellas Pharma US INC | $48.89 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $48.12 | 2021-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.81 | 2023-2024 | Jardiance, Synjardy |
| Phathom Pharmaceuticals, INC. | $34.06 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $24.24 | 2023 | Heplisav-B |
| Madrigal Pharmaceuticals | $20.94 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $18.31 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $18.01 | 2025 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.